Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes - PubMed (original) (raw)
Multicenter Study
. 2009 Feb 1;103(3):295-300.
doi: 10.1016/j.amjcard.2008.09.081. Epub 2008 Nov 19.
Affiliations
- PMID: 19166678
- DOI: 10.1016/j.amjcard.2008.09.081
Multicenter Study
Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes
Benjamin A Olenchock et al. Am J Cardiol. 2009.
Abstract
Beta blockers have a proven benefit in the management of patients with acute coronary syndromes (ACS) and for secondary prevention of coronary events. Current guidelines list such reactive airway diseases (RADs) such as asthma and chronic obstructive pulmonary disease as relative contraindications to beta-blocker use. However, the co-morbid burden of RAD and coronary heart disease is substantial, and data suggest that the treatment benefit of beta blockers is shared by patients with RAD. The Get with the Guidelines (GWTG) database was used to evaluate use of beta blockers within 24 hours of admission and at discharge in patients with ACS with (n = 12,967) and without (n = 81,140) a history of RAD. Data were collected in 435 hospitals between January 2000 and September 2006. A multivariable logistic regression model was used to determine predictors of beta-blocker treatment. In patients with no RAD history, beta-blocker prescription rates were 78.3% at admission and 88.7% at discharge; in patients with a RAD history, rates were 65.6% at admission and 77.2% at discharge. Compared with patients with no history of RAD, patients with a history of RAD were 42% less likely (odds ratio 0.58, confidence interval 0.54 to 0.62, p <0.0001) to receive a beta blocker upon admission and 55% less likely (odds ratio 0.45, confidence interval 0.41 to 0.48, p <0.0001) to receive a beta blocker at discharge in multivariable analysis. Among all other clinical factors, RAD history was the most significant predictor of likelihood of not receiving a beta blocker at admission or discharge. Receipt of beta blockers within 24 hours after admission was associated with a lower in-hospital mortality rate for patients with RAD (odds ratio = 0.52, p <0.001) and for patients without RAD (odds ratio = 0.38, p <0.001). Careful assessment of beta-blocker safety and RAD severity by physicians is needed to improve beta-blocker prescription rates in this large group of patients with ACS.
Similar articles
- Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG; Canadian ACS Registries Investigators. Yan AT, et al. Am Heart J. 2007 Dec;154(6):1108-15. doi: 10.1016/j.ahj.2007.07.040. Epub 2007 Sep 14. Am Heart J. 2007. PMID: 18035083 - Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM. Brooks TW, et al. Pharmacotherapy. 2007 May;27(5):684-90. doi: 10.1592/phco.27.5.684. Pharmacotherapy. 2007. PMID: 17461703 - Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS, Bajorek BV. Vermeer NS, et al. J Clin Pharm Ther. 2008 Dec;33(6):591-601. doi: 10.1111/j.1365-2710.2008.00950.x. J Clin Pharm Ther. 2008. PMID: 19138236 - Beta-blocker underuse in secondary prevention of myocardial infarction.
Everly MJ, Heaton PC, Cluxton RJ Jr. Everly MJ, et al. Ann Pharmacother. 2004 Feb;38(2):286-93. doi: 10.1345/aph.1C472. Epub 2003 Dec 30. Ann Pharmacother. 2004. PMID: 14742768 Review. - Should beta-blockers be used in the treatment of cocaine-associated acute coronary syndrome?
Page RL 2nd, Utz KJ, Wolfel EE. Page RL 2nd, et al. Ann Pharmacother. 2007 Dec;41(12):2008-13. doi: 10.1345/aph.1H643. Epub 2007 Oct 23. Ann Pharmacother. 2007. PMID: 17956961 Review.
Cited by
- Early β-blocker use and in-hospital outcomes in patients with chronic obstructive pulmonary disease hospitalized with acute coronary syndrome: findings from the CCC-ACS project.
Zhang T, Wang X, Zhang Y, Feng T, Zhou Y, Zhao L. Zhang T, et al. Front Cardiovasc Med. 2024 Jul 11;11:1385943. doi: 10.3389/fcvm.2024.1385943. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39055663 Free PMC article. - The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports.
Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. Bennett M, et al. ERJ Open Res. 2021 Mar 1;7(1):00801-2020. doi: 10.1183/23120541.00801-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33681344 Free PMC article. Review. - G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.
Wendell SG, Fan H, Zhang C. Wendell SG, et al. Pharmacol Rev. 2020 Jan;72(1):1-49. doi: 10.1124/pr.118.016899. Pharmacol Rev. 2020. PMID: 31767622 Free PMC article. Review. - Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study.
Wang WH, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Wang WH, et al. Heart Vessels. 2019 Jul;34(7):1158-1167. doi: 10.1007/s00380-019-01341-0. Epub 2019 Jan 24. Heart Vessels. 2019. PMID: 30680495 - Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study.
Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Morales DR, et al. BMC Med. 2017 Jan 27;15(1):18. doi: 10.1186/s12916-017-0781-0. BMC Med. 2017. PMID: 28126029 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical